Lights, fluorescence, action—Influencing wound treatment plans including debridement of bacteria and biofilms
Ashley Jacob1, Laura M. Jones1, Raymond J. Abdo2, Sebastian F. Cruz-Schiavone3, Robert Skerker4, Wayne J. Caputo5, Nathan Krehbiel1, Audrey K. Moyer-Harris1, Alyssa McAtee6, Isabel Baker1, Micaela D. Gray1, Monique Y. Rennie1
1MolecuLight Inc., Toronto, Ontario, Canada 2St. Louis Foot & Ankle, St. Louis, Missouri, USA 3Adamant Medical Group, Pittsburgh, Pennsylvania, USA 4Atlantic Health, Morristown, New Jersey, USA 5Clara Maass Medical Center, Belleville, New Jersey, USA 6Agiliti Health, Inc., Minneapolis, Minnesota, USA
Int Wound J. 2023;1–10.
Related Publications
Detection of Bacterial Burden
Detection of Bacterial Burden
Detection of Bacterial Burden
Detection of Bacterial Burden
Detection of Bacterial Burden
Detection of Bacterial Burden
MolecuLight Headquarters
425 University Avenue Suite 700 Toronto, ON M5G 1T6 Canada
US Address MolecuLight Corp. 2403 Sidney Street, Suite 209 Pittsburgh, PA 15203
T. 1-877-818-4360
North American Toll Free:
1-877-818-4360
F.+1 647-362-4730
E: info@moleculight.com
©2024
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.